Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 58

1.

Position-dependent FUS-RNA interactions regulate alternative splicing events and transcriptions.

Ishigaki S, Masuda A, Fujioka Y, Iguchi Y, Katsuno M, Shibata A, Urano F, Sobue G, Ohno K.

Sci Rep. 2012;2:529. doi: 10.1038/srep00529. Erratum in: Sci Rep. 2013;3:3301.

2.

Widespread binding of FUS along nascent RNA regulates alternative splicing in the brain.

Rogelj B, Easton LE, Bogu GK, Stanton LW, Rot G, Curk T, Zupan B, Sugimoto Y, Modic M, Haberman N, Tollervey J, Fujii R, Takumi T, Shaw CE, Ule J.

Sci Rep. 2012;2:603. doi: 10.1038/srep00603.

3.

FUS-regulated region- and cell-type-specific transcriptome is associated with cell selectivity in ALS/FTLD.

Fujioka Y, Ishigaki S, Masuda A, Iguchi Y, Udagawa T, Watanabe H, Katsuno M, Ohno K, Sobue G.

Sci Rep. 2013;3:2388. doi: 10.1038/srep02388. Erratum in: Sci Rep. 2013;3:3300.

4.

ALS-associated mutation FUS-R521C causes DNA damage and RNA splicing defects.

Qiu H, Lee S, Shang Y, Wang WY, Au KF, Kamiya S, Barmada SJ, Finkbeiner S, Lui H, Carlton CE, Tang AA, Oldham MC, Wang H, Shorter J, Filiano AJ, Roberson ED, Tourtellotte WG, Chen B, Tsai LH, Huang EJ.

J Clin Invest. 2014 Mar;124(3):981-99. doi: 10.1172/JCI72723.

5.

FUS-mediated alternative splicing in the nervous system: consequences for ALS and FTLD.

Orozco D, Edbauer D.

J Mol Med (Berl). 2013 Dec;91(12):1343-54. doi: 10.1007/s00109-013-1077-2. Review.

PMID:
23974990
6.

ALS-associated FUS mutations result in compromised FUS alternative splicing and autoregulation.

Zhou Y, Liu S, Liu G, Oztürk A, Hicks GG.

PLoS Genet. 2013 Oct;9(10):e1003895. doi: 10.1371/journal.pgen.1003895.

7.

Position-specific binding of FUS to nascent RNA regulates mRNA length.

Masuda A, Takeda J, Okuno T, Okamoto T, Ohkawara B, Ito M, Ishigaki S, Sobue G, Ohno K.

Genes Dev. 2015 May 15;29(10):1045-57. doi: 10.1101/gad.255737.114.

8.

Beta-catenin interacts with the FUS proto-oncogene product and regulates pre-mRNA splicing.

Sato S, Idogawa M, Honda K, Fujii G, Kawashima H, Takekuma K, Hoshika A, Hirohashi S, Yamada T.

Gastroenterology. 2005 Oct;129(4):1225-36.

PMID:
16230076
9.

From transcriptomic to protein level changes in TDP-43 and FUS loss-of-function cell models.

Colombrita C, Onesto E, Buratti E, de la Grange P, Gumina V, Baralle FE, Silani V, Ratti A.

Biochim Biophys Acta. 2015 Dec;1849(12):1398-410. doi: 10.1016/j.bbagrm.2015.10.015.

PMID:
26514432
10.

FUS-mediated regulation of alternative RNA processing in neurons: insights from global transcriptome analysis.

Masuda A, Takeda J, Ohno K.

Wiley Interdiscip Rev RNA. 2016 May;7(3):330-40. doi: 10.1002/wrna.1338. Review.

PMID:
26822113
11.

Fused in sarcoma (FUS) protein lacking nuclear localization signal (NLS) and major RNA binding motifs triggers proteinopathy and severe motor phenotype in transgenic mice.

Shelkovnikova TA, Peters OM, Deykin AV, Connor-Robson N, Robinson H, Ustyugov AA, Bachurin SO, Ermolkevich TG, Goldman IL, Sadchikova ER, Kovrazhkina EA, Skvortsova VI, Ling SC, Da Cruz S, Parone PA, Buchman VL, Ninkina NN.

J Biol Chem. 2013 Aug 30;288(35):25266-74. doi: 10.1074/jbc.M113.492017.

12.

Transportin 1 accumulates specifically with FET proteins but no other transportin cargos in FTLD-FUS and is absent in FUS inclusions in ALS with FUS mutations.

Neumann M, Valori CF, Ansorge O, Kretzschmar HA, Munoz DG, Kusaka H, Yokota O, Ishihara K, Ang LC, Bilbao JM, Mackenzie IR.

Acta Neuropathol. 2012 Nov;124(5):705-16. doi: 10.1007/s00401-012-1020-6.

PMID:
22842875
13.

Mislocalised FUS mutants stall spliceosomal snRNPs in the cytoplasm.

Gerbino V, Carrì MT, Cozzolino M, Achsel T.

Neurobiol Dis. 2013 Jul;55:120-8. doi: 10.1016/j.nbd.2013.03.003.

PMID:
23523636
14.

FUS binds the CTD of RNA polymerase II and regulates its phosphorylation at Ser2.

Schwartz JC, Ebmeier CC, Podell ER, Heimiller J, Taatjes DJ, Cech TR.

Genes Dev. 2012 Dec 15;26(24):2690-5. doi: 10.1101/gad.204602.112.

15.

Coordinate regulation of transcription and splicing by steroid receptor coregulators.

Auboeuf D, Hönig A, Berget SM, O'Malley BW.

Science. 2002 Oct 11;298(5592):416-9.

16.

Ataxin-2 interacts with FUS and intermediate-length polyglutamine expansions enhance FUS-related pathology in amyotrophic lateral sclerosis.

Farg MA, Soo KY, Warraich ST, Sundaramoorthy V, Blair IP, Atkin JD.

Hum Mol Genet. 2013 Feb 15;22(4):717-28. doi: 10.1093/hmg/dds479.

PMID:
23172909
17.

An autopsied case of sporadic adult-onset amyotrophic lateral sclerosis with FUS-positive basophilic inclusions.

Matsuoka T, Fujii N, Kondo A, Iwaki A, Hokonohara T, Honda H, Sasaki K, Suzuki SO, Iwaki T.

Neuropathology. 2011 Feb;31(1):71-6. doi: 10.1111/j.1440-1789.2010.01129.x.

PMID:
20573033
18.

Frameshift and novel mutations in FUS in familial amyotrophic lateral sclerosis and ALS/dementia.

Yan J, Deng HX, Siddique N, Fecto F, Chen W, Yang Y, Liu E, Donkervoort S, Zheng JG, Shi Y, Ahmeti KB, Brooks B, Engel WK, Siddique T.

Neurology. 2010 Aug 31;75(9):807-14. doi: 10.1212/WNL.0b013e3181f07e0c.

19.

Alternative promoter usage and alternative splicing contribute to mRNA heterogeneity of mouse monocarboxylate transporter 2.

Zhang SX, Searcy TR, Wu Y, Gozal D, Wang Y.

Physiol Genomics. 2007 Dec 19;32(1):95-104.

Supplemental Content

Support Center